Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. H-NMR analysis of PLGA, LRA, and PLGA-LRA conjugates.
  • Fig. S2. HPLC analysis of PLGA-LRA conjugates.
  • Fig. S3. Colloidal stability of LRA-loaded LCNPs.
  • Fig. S4. Flow cytometry dot plots showing the entire gating strategy used to identify GFP+ cell populations of J-Lat A1 cells.
  • Fig. S5. In vitro dose-response HIV-1 latency reversal and cytotoxicity by free butyric acid or its prodrug inserted into LCNPs.
  • Fig. S6. In vitro dose-response HIV-1 latency reversal and cytotoxicity by smaller Ing3A-cbLCNP compared to previous Ing3A-LCNP formulation.
  • Fig. S7. Comparison of CD69 expression between CD8+ and CD4+ T cells from NHP PBMCs after treating with Ing3A formulations.
  • Fig. S8. Pilot mouse studies comparing biodistribution of different LCNP formulations.
  • Fig. S9. Flow cytometry dot plots showing the entire gating strategy applied in Fig. 5.
  • Fig. S10. Representative images of mouse subcutaneous tissues at 3 days after administration of different Ing3A formulations.
  • Fig. S11. Targeted LCNP-formulated Ing3A is nontoxic to CD4+ and CD8+ T cells in mouse LNs after subcutaneous dosing.
  • Table S1. Physicochemical properties of LCNP-formulated LRAs with unsatisfactory low drug loading.
  • Table S2. Physicochemical properties of LCNPs made of various PLGAs.
  • Table S3. Parameters from fitting to LRA release kinetics.
  • Table S4. Parameters from fitting to LRA dose-response curve.
  • Table S5. Synthesis optimization for smaller LCNPs.

Download PDF

Files in this Data Supplement: